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ABSTRACT 
 
Protein phosphatases play a key role in balancing cellular responses to transforming growth 
factor-β (TGFβ) signals. Several protein phosphatases have been attributed roles in the regulation 
of the TGFβ pathway. Among these, PPM1A is the only phosphatase reported to 
dephosphorylate SMAD2/3 in the nucleus. However we observed PPM1A exclusively in the 
cytoplasmic fractions independently of TGFβ treatment in all cells tested. These observations 
imply that a bona fide nuclear SMAD2/3 phosphatase remains elusive. In this study, we report a 
role for protein phosphatase 5 (PP5) in the TGFβ pathway. We identified PP5 as an interactor of 
SMAD2/3. Interestingly, in mouse embryonic fibroblast cells derived from PP5-null mice, 
TGFβ-induced transcriptional responses were significantly enhanced. This enhancement is due to 
the increased levels of SMAD3 protein observed in PP5-null MEFs compared to the wild type. 
No differences in the levels of SMAD3 transcripts were observed between the wild type and 
PP5-null MEFs. While PP5 is capable of dephosphorylating SMAD3-tail in overexpression 
assays, we demonstrate that its activity is essential in controlling SMAD3 protein levels in 
MEFs. We propose that PP5 regulates the TGFβ pathway in MEFs by regulating the expression 
of SMAD3 protein levels. 
1. Introduction 
 
TGFβ signalling plays a pivotal role through vertebrate development and tissue homeostasis. 
Concise control of cellular responses to TGFβ signals is essential to ensure proper developmental 
progression and tissue differentiation. Upon binding their respective receptor kinase pairs at the 
cell-surface, TGFβ ligands exert cellular responses by inducing a cascade of phosphorylation of 
key intra-cellular signal-mediators, including receptors and SMAD transcription factors (1). 
Dephosphorylation of these mediators by protein phosphatases is a key step in balancing the 
potency and duration of TGFβ signalling (2). Protein phosphatases that indirectly modulate the 
expression, localisation or stability of key TGFβ pathway mediators could also influence the 
outcome of TGFβ signalling (2). 
 
SMAD transcription factors mediate the TGFβ signals inside the cell upon phosphorylation of 
the C-terminal tail SXS motif (hereafter referred to as tail) by the type I receptor kinases (1). The 
tail-phosphorylated SMADs then translocate to the nucleus, where they interact with SMAD4 
and other co-factors to initiate or repress transcription of hundreds of target genes (1). The fate of 
SMADs following signal initiation, their nuclear translocation and transcriptional control of the 
target genes is generally well established. However, the precise details of the subsequent fate of 
the tail-phosphorylated SMADs are not completely clear. The polyubiquitin-mediated 
degradation and/or recycling by dephosphorylation of SMADs are two outcomes that have 
received the most scrutiny (2-11). As the tail-phosphorylated SMADs are observed in the 
nucleus, the phosphatases that catalyse their dephosphorylation are most likely nuclear. Further 
observations, including that receptor kinase inhibition results in pronounced cytoplasmic 
distribution of dephosphorylated SMAD2/3, support the existence of R-SMAD phosphatases in 
the nucleus (12-14). Consistent with this notion, PPM1A (also known as PP2C) was reported to 
be a SMAD2/3-tail phosphatase in the nucleus (11). In contrast, two cytoplasmic phosphatases, 
namely PP2A and MTMR4, have been proposed to act as SMAD phosphatases (15,16). PP2A 
has been reported to act as SMAD3-tail phosphatase only under hypoxia (15). MTMR4 has been 
reported to dephosphorylate SMAD2/3 in the cytoplasm and attenuate TGFβ signalling (16). 
Despite these reports, evidence for the role of these phosphatases on the TGFβ pathway has not 
been confirmed in knockout mouse models or cells. 
 
In order to uncover novel regulators of the TGFβ pathway, including protein phosphatases, a 
proteomic approach was employed to identify protein interactors of SMAD2/3. From these 
screens, protein phosphatase 5 (PP5) was identified as an interactor of SMAD2 and SMAD3. 
The proteomic screen did not identify PPM1A, PP2A and MTMR4 as interactors of SMAD2/3. 
PP5 is a serine/threonine phosphatase that belongs to the phospho-protein phosphatase (PPP) 
family of phosphatses (17). Many members of the PPP family are oligomeric holoenyzymes that 
require a number of regulatory, catalytic and scaffold subunits to be active. PP5, however, has its 
catalytic, regulatory and substrate-binding domains within one polypeptide (17,18). PP5 is 
reported to mediate the dephosphorylation of a number of proteins including GRα, Chk1, 53BP1 
and IKKβ (19-22). However, its role in TGFβ signalling has not been investigated. PP5 has been 
shown to localise in both the nucleus and cytoplasm (23,24). Mutation of its nuclear localisation 
motif located in the C-terminal region abolishes its ability to localise to the nucleus (25). 
 
In this study, we evaluate the roles of SMAD-interacting phosphatases, in particular PP5, in the 
TGFβ pathway. We also investigate how the localisation of reported nuclear SMAD phosphatase 
PPM1A, and a close family member PPM1B, is affected upon TGFβ induction.  
 
2. Materials and methods 
 
2.1. Materials and general methods 
 
Mammalian expression constructs for PPM1A, PP5, SMAD1, SMAD3, SMAD4 and SMAD7 
were cloned into pCMV5 vectors expressing N-terminally FLAG- or HA-tagged proteins. 
Untagged PP5 and a catalytically inactive mutant of PP5 based on the structure of PP5 (26)(a 
kind gift from Tricia Cohen; the Asp residue at position 274 of PP5 was mutated to Ala; 
unpublished findings) were cloned into a pBABE-hygro retroviral vector (Cell Biolabs). pCMV-
Gag-Pol and pCMV-VSVG constructs were purchased from Cell Biolabs, Inc. All DNA 
constructs used were verified by DNA sequencing, performed by DNA Sequencing & Services 
(MRC PPU, College of Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) 
using Applied Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 
automated capillary DNA sequencer. pGL2.11 3TP-Lux reporter construct was a kind gift from 
Joan Massagué. The pGL4.11 LUC2p-BRE (BMP-Response Element) and pGL4.11 LUC2p-
SRE (SMAD-Response Element) reporter constructs were based on SMAD-binding sequences 
within ID1 (BMP-target gene) and PAI-1 (TGFβ target gene) promoters respectively. Renilla 
luciferase reporter was used as transfection control. After stimulation, cells were lysed under 
passive conditions and the reporter activity assayed with Dual-Luciferase™ kit (Promega). 
Recombinant Activin A, TGFβ1 and BMP-2 were purchased from R&D Systems, MG-132 from 
Tocris, Bortezomib from LC Laboratories and Okadiac acid from Merck. The antibodies 
recognising P-SMAD1 (Ser463/465), P-SMAD2 (Ser465/467), SMAD2/3, SMAD3, Lamin A/C 
and GAPDH were purchased from Cell Signalling, Histone 1B from Abcam, P-SMAD3 
(Ser423/425) was purchased from Rockland Inc., PPM1B from R&D Systems (IB) and Bethyl 
Laboratories (IF). Peptide antibodies against human PPM1A (aa 369-382), PP5 (aa 471-485), 
SMAD1 (aa 144-268), SMAD2 (aa 87-107) and SMAD3 (aa 158-178) were generated by 
injecting peptides into sheep and affinity purified; some have been described previously (27,28). 
HRP-coupled anti-FLAG (Sigma) and anti-HA antibodies (Roche) were also employed. Proteins 
were detected by HRP-coupled secondary antibodies (Pierce) or protein G-HRP antibodies 
(BioRad) and visualised with enhanced chemiluminescence (Pierce). 
   
2.2. Cell Culture, Transfections and Stimulations 
 
HaCaT keratinocytes, HEK293 cells, HUVEC cells, HeLa cells, mouse embryonic fibroblasts 
(MEFs), Swiss 3T3 cells, HepG2 cells, Neuro2A cells, G361 cells, U87 cells, A549 cells and 
MDA231 cells were cultured at 37°C in an atmosphere with 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS, 1X Penicillin/Streptomycin solution 
and 1X L-glutamine. Sodium pyruvate (1X) and non-essential amino acids (0.1mM) were 
supplemented for Neuro2A, G361 and U87 cells. Mouse ES cells (29) and RAW macrophage 
cells (27) were maintained as described. The transfection of cDNA vectors was performed as 
described previously (3). Transfection of siRNA oligonucleotides against FoxO4, PPM1A and 
PPM1B was performed using Lipofectamine 2000 reagent as described previously (3). The 
siRNA oligos used are as follows: PPM1A: GUAUCGCCAGAAGCAGUGATT; PPM1B: 
UAGACUGAAUCCACAUAGATT. The FoxO4 siRNA was described previously (7). 
 
2.3. Generation of PP5 -/- MEFs stably expressing wild type PP5 or catalytically inactive PP5-
PD mutant 
 
Retroviral pBABE-hygro constructs (1µg each) encoding PP5 or PP5-PD were co-expressed 
with CMV-Gag/Pol (0.9µg) and CMV-VSVG (0.1µg) constructs in HEK-293T cells. 
Retroviruses were collected 48h-post transfection from the culture media by filtering it through 
0.45µm filters onto sterile falcon tubes. PP5 -/- MEFs, plated at ~40% confluent, were infected 
by transferring the filtered retroviruses directly onto the cells and 8µg/ml Polybrene reagent was 
added to aid infection. 24h-post infection, cells were cultured in the presence of hygromycin B 
100µg/ml for selection of infected cells. Western blots on cell extracts with a PP5 antibody was 
used to verify infection of the targets.  
 
2.4. RNA isolation, cDNA preparation and analysis of transcripts by qRT-PCR 
 
Total RNA was isolated from cells using the RNeasy kit (Qiagen). cDNA was prepared from 
1µg of RNA using the i-Script Kit (Bio-Rad). qRT-PCR was performed in 96-well plate format 
using iQ5™ Real Time PCR detection system (BioRad), where each 20µl reaction included 1% 
cDNA preparation, 0.5µM primers and 10µl SYBR Green (Quanta). The mouse primer 
sequences (5’-3’) used for qRT-PCR are as follows: GAPDH F: 
TATGATGACATCAAGAAGGTGG; R: CATTGTCATACCAGGAAATGAG; PP5 F: 
CTGGAGGAGAATCAACTGGA; R: CCATCTGGTCACAATAGTTGG; Gadd45γ F: 
GACTTTGGCGGACTCGTAGA; R: ACTCTGGAAGAAGTCCGTGG; c-MYC F: 
CTCAGTGGTCTTTCCCTACC; R: CTTGCTCTTCTTCAGAGTCG; SMAD3 F: 
CGTAATTCATGGTGGCTGTG; R: ACCAAGTGCATTACCATCCC; SnoN F: 
GAATGGAATTGCCATCATGG; R: GATTGATGAATTTGTCTCTGCC. Each qRT-PCR 
reaction was performed in triplicates and the data presented is a representative of three 
independent biological repeats. 
 
2.5. Other Assays 
 
Immunoblots were performed as described previously (27). For immunostaining, cells were fixed 
in 4% PFA and immunostained with the indicated antibodies as described previously (7). 
Nuclear and cytoplasmic fractionations were performed using a Nuclear and Cytoplasmic 
Extraction Kit (Pierce). For chemical cross-linking with Dithiobis (succinimidyl propionate) 
(DSP; Thermo), cells were lysed in ice-cold HEPES lysis buffer (40mM HEPES pH 7.4, 120mM 
NaCl, 1mM EDTA, 10mM sodium pyrophosphate, 50mM sodium fluoride, 1.5mM sodium 
orthovanadate, 1% Triton X-100, complete protease inhibitors (Roche)) containing 2.5mg/ml 
DSP, freshly added prior to lysis. Lysates were incubated at 4°C for 30min before cross-linking 
was quenched with 1M Tris pH 7.5 at a final concentration of 0.2M. Extracts were further 
incubated for 30min at 4°C before pre-clearing and immunoprecipitation (IP). For IPs, antibodies 
were pre-coupled to protein G-Sepharose beads. IPs were performed for 3h at 4°C with constant 
agitation, beads were then washed twice with lysis buffer containing 0.5M NaCl and once with 
TE buffer (50mM Tris pH 7.4 and 0.1mM EGTA) at 4°C before boiling for 5min in SDS sample 
buffer containing 50mM dithiothreitol (DTT). 
 
2.6. Statistical analysis 
 
Data are presented as the mean ± SD. Statistical significance of differences between 
experimental groups was assessed using the two-way analysis of variance (ANOVA) test with 
Bonferroni posttests. Differences in means were considered significant if p<0.05. Differences 
with p<0.05 were annotated as “*”, p<0.005 were annotated as “**” and p<0.001 were annotated 
as “***”.    
 
3. Results 
 
3.1. PPM1A/B are cytoplasmic 
 
In order to define the roles of phosphatases following TGFβ-induced nuclear accumulation of 
tail-phosphorylated SMAD2/3, we initially sought to investigate and validate the roles of some 
known nuclear SMAD2/3 phosphatases in multiple cell systems. We separated human 
keratinocyte HaCaT cells, mouse ES cells, breast cancer MDA231 cells, HUVEC endothelial 
cells and HEK293 cells into nuclear and cytoplasmic fractions. Rather surprisingly, PPM1A was 
observed only in the cytoplasmic fractions in all of the cells (Figure 1A). We confirmed the 
PPM1A immunoreactive band by immunoblotting HaCaT extracts transfected with PPM1A 
siRNA or FoxO4 siRNA controls (Figure 1A; last two lanes). The transfections of PPM1A siRNA 
resulted in the reduction of the expression of PPM1A protein by ~90% (Figure 1A). As expected, 
GAPDH and Histone 1B fractionated with the cytoplasmic and nuclear fractions respectively 
(Figure 1A). We also investigated the localisation of PPM1B, which is closely related to PPM1A 
(17). Like PPM1A, PPM1B fractionated exclusively with the cytoplasmic fractions in all the 
cells tested (Figure 1A). The cytoplasmic localisation of PPM1A that we observed in various cell 
lines directly contradicted with published reports that have employed similar fractionation 
technique (11). Therefore we extended our investigation of PPM1A localisation to more cell 
types, including HeLa cells, mouse embryonic fibroblasts, Swiss 3T3 cells, liver hepatocellular 
carcinoma HepG2 cells, RAW macrophages, neuroblastoma Neuro2A cells, G361 melanoma 
cells, and U87MG glioblastoma cells. In all cases PPM1A was detected exclusively in 
cytoplasmic fractions (Figure 1B). In order to ensure that the cytoplasmic localisation of 
PPM1A/B was not due to inefficient fractionation techniques, we sought to verify their 
subcellular localisation by immunofluorescence. The PPM1A antibody used in our immunoblot 
assays yielded pan-cellular fluorescence in HaCaT cells transfected with or without PPM1A 
siRNA (data not shown). Therefore, we transfected HaCaT cells with N-terminal HA-tagged 
PPM1A, and demonstrate that the HA-antibody only stains the cytoplasm of the transfected cells 
while the adjacent untransfected cells are not stained (Figure 1C). Furthermore, HA-PPM1A was 
detected exclusively in the cytoplasmic fraction in these cells (Figure 1C, bottom panel). Using a 
PPM1B antibody for immunostaining, we demonstrate that in HaCaT cells endogenous PPM1B 
localises mainly to the cytoplasm (Figure 1D). The cytoplasmic staining was greatly reduced 
when cells were transfected with PPM1B siRNA (Figure 2B). Furthermore, PPM1B is detected 
only in the cytoplasmic fractions of HaCaT cells (Figure 1D; bottom panel). In HaCaT cells 
transfected with PPM1B siRNA, the expression of PPM1B is depleted >80% over control cells 
(Figure 1D; bottom panel). 
  
3.2. TGFβ ligands do not alter the cytoplasmic localisation of PPM1A/B 
 
Faced with the observations from immunostaining and immunoboltting assays in HaCaT and 
other cells that PPM1A/B are cytoplasmic phosphatases, we sought to investigate whether 
treatment of cells with TGFβ (Figure 2A) or BMP (Figure 2B) altered their localisation. We 
performed time course stimulations in HaCaT cells with TGFβ or BMP for up to 20h prior to 
nuclear cytoplasmic fractionation. TGFβ or BMP treatment did not alter the cytoplasmic 
localisation of PPM1A, while inducing nuclear accumulation of phospho-tail SMAD2 or 
phospho-tail SMAD1 respectively (Figure 2A&B). 
 
3.3. PP5 interacts with SMAD2/3 but not SMAD1 
 
Our observations of cytoplasmic localisation of PPM1A suggested that a nuclear phosphatase for 
SMAD2/3 remained to be identified. Interestingly in a proteomic screen we undertook to identify 
novel interactors of SMAD2/3, we identified protein phosphatase 5 (PP5) in GFP-SMAD2 and 
GFP-SMAD3 immunoprecipitates (IPs) but not in GFP-alone IPs (data not shown). In order to 
verify the interactions between endogenous proteins, IPs of SMAD2 and SMAD3 or SMAD1 
used as control were subjected to PP5 immunoblots. Endogenous PP5 was detected in SMAD2 
and SMAD3 IPs but not in SMAD1 or control IgG IPs (Figure 3A&B). The levels of PP5 
detected in the SMAD2/3-IPs did not change by TGFβ treatment, which resulted in 
phosphorylation of both SMAD2 and SMAD3 (Figure 3A). BMP treatment did not induce 
interaction between SMAD1 and PP5 (Figure 3B). 
 
3.4. PP5 overexpression leads to the dephosphorylation of SMAD3-tail 
 
PP5 belongs to the PPP family of phosphatases, which can be inhibited by okadaic acid (OA) 
(30). To study the effects of PP5 on TGFβ signalling, an in vivo dephosphorylation assay was 
established (Figure 4A). Firstly, HaCaT cells were treated with TGFβ for 45min in order to 
induce optimal phosphorylation of SMAD2/3-tail. At this point the ligands were removed by 
washing cells twice with DMEM. The subsequent rate of dephosphorylation of SMAD2/3 was 
tracked by immunoblotting cell extracts lysed at specific time points using P-SMAD3 antibody. 
Preincubating cells with OA in the above assay prolongs the phosphorylation of SMAD3 at 
120min following ligand removal (Figure 4A). This indicates that an OA-sensitive phosphatase 
acts to inhibit the phosphorylation of SMAD2/3-tail, either directly or indirectly. In order to test 
whether PP5 could dephosphorylate TGFβ or Activin A-induced phospo-SMAD3, mammalian 
expression constructs encoding HA-PP5 and FLAG-SMADs 1, 3, 4 and 7 were co-expressed in 
HEK293T cells. Cells were treated with BMP or Activin A to induce tail-phosphorylation of 
FLAG-SMAD1 or FLAG-SMAD3 respectively. PP5 completely abolished Activin A-induced 
phosphorylation of Flag-SMAD3 but not BMP-induced phosphorylation of FLAG-SMAD1 or 
endogenous SMAD1 (Figure 4B). 
 
3.5. PP5 modulates TGFβ-induced responses in mouse embryonic fibroblasts 
 
In order to establish the role of PP5 on the TGFβ pathway, we employed mouse embryonic 
fibroblasts (MEF) cells derived from both wild type (WT) and PP5 knockout (PP5-null) mice 
(31). We employed two methods: exploiting TGFβ-responsive luciferase constructs and 
monitoring the changes in expression of TGFβ-regulated genes by qRT-PCR. Significant 
increases in reporter activity were observed in the PP5-null cells after TGFβ stimulation when 
compared to the WT cells (Figure 5A). This increase was detected with two different TGFβ-
responsive luciferase reporter constructs (Figure 5A). However, when a BMP-responsive 
luciferase construct (BRE) was employed as a negative control, the relative luciferase activity in 
BMP-stimulated PP5-null cells was similar to the WT cells (Figure 5B). Furthermore, PP5-null 
cells displayed an increased expression of three TGFβ responsive genes (SnoN, c-MYC and 
Gadd45γ) compared to the WT cells following stimulation with TGFβ (Figure 5C). As expected, 
PP5 transcripts were absent from PP5-null MEFs. The levels of SMAD3 transcripts were similar 
in both PP5-null and WT MEFs (Figure 5D). These observations were consistent with the 
possibility of PP5 acting as a SMAD2/3 phosphatase.  
 
3.6. PP5 modulates the expression of SMAD3 protein in mouse embryonic fibroblasts 
 
Next we monitored the phosphorylation of SMAD3 upon TGFβ stimulation (Figure 6A). When 
two concentrations of TGFβ were used in a time course experiment, there was a modest increase 
in SMAD3 phosphorylation observed in extracts from PP5-null MEFs than WT. The difference 
was more prominent at latter time points, especially when cells were treated with 25pM TGFβ 
(Figure 6A). Rather surprisingly, the protein levels of SMAD3 were observed to be consistently 
higher in PP5-null cells compared to WT MEFs while GAPDH levels were similar between all 
samples (Figure 6A). Next we tracked the levels of phospho-SMAD3 following removal of 
TGFβ ligand from media as described above. The levels of phospho-SMAD3 were higher in 
PP5-null MEFs in comparison to the WT at both 0min and 120min time points following the 
removal of TGFβ ligand (Figure 6B). However, the levels of SMAD3 protein were also 
consistently higher in PP5-null MEFs compared to the WT (Figure 6B). As the expression of 
SMAD3 transcripts in both WT and PP5-null MEFs were similar (Figure 5D), we investigated 
whether PP5 was inducing proteosomal degradation of SMAD3 in WT MEFs. Inhibition of the 
proteasome by inhibitors MG-132 and bortezomib did not rescue the levels of SMAD3 protein in 
the WT cells compared to the PP5-null cells (Figure 6C). 
 
3.7. PP5 activity is essential for modulation of the expression of SMAD3 protein 
 
The changes in the SMAD3 protein levels observed in WT vs. PP5-null MEFs could be due to 
cell type differences. Therefore, in order to definitively establish the role for PP5 in the 
regulation of SMAD3 protein expression, we stably re-introduced WT (PP5-/- WT) and 
catalytically inactive PP5-PD mutant (PP5-/- PD) in PP5-null MEFs. The level of expression of 
PP5 protein in these MEFs was comparable to that seen in wild type MEFs (Figure 7A). Next we 
investigated the TGFβ-induced SMAD3-tail phosphorylation in these cells. The levels of 
phosho-SMAD3 induced by 5pM or 25pM TGFβ were lower in PP5-/- WT cells compared to 
PP5-/- empty or PP5-/- PD cells (Figure 7B). Interestingly, the levels of SMAD3 protein were 
also lower in PP5-/- WT cells compared to both PP5-/- empty and PP5-/- PD cells indicating that 
PP5 catalytic activity is responsible for regulating SMAD3 protein levels in these cells (Figure 
7B). 
 
4. Discussion 
 
Identification and characterisation of a bona fide nuclear SMAD2/3-tail phosphatase capable of 
terminating TGFβ signalling has long been one of the most sought-after challenges in the TGFβ 
field (2). As such, when PPM1A was described as the nuclear SMAD1/2/3-tail phosphatase (11), 
this challenge appeared to have been finally resolved. However, our findings that PPM1A as well 
as the closely related PPM1B both localise to the cytoplasm independent of TGFβ treatment 
raises doubts over the validity of PPM1A/B as nuclear SMAD2/3 phosphatases. In all of the 13 
different cells that we fractionated, PPM1A was clearly only detected in the cytoplasmic 
fractions. These observations directly contradict the published findings using similar 
fractionation methodology (11). Our observations raise two possibilities on the role of PPM1A as 
SMAD2/3-tail phosphatases: i. PPM1A acts as SMAD2/3-phosphatases in the cytoplasm and 
affects cytoplasmic levels of phospho-SMAD2/3-tail thereby affecting the TGFβ pathway. 
PPM1A could therefore have an analogous role to PP2A and MTMR4 that have been reported to 
act as cytoplasmic phosphatases against phospho-SMAD2/3-tail (15,16). ii. PPM1A does not 
target phospho-SMAD2/3-tail and any effects on the TGFβ pathway signalling may be indirect. 
Both these possibilities could easily be confirmed in cells derived from PPM1A-knockout mice 
(32). As silencing of PPM1A alone by RNAi was clearly demonstrated to enhance TGFβ 
pathway signalling (11), cells derived from PPM1A-knockout would be expected to display 
enhanced TGFβ signalling. Indeed the authors of the original study describing PPM1A as a 
SMAD2/3-tail phosphatase have reported the isolation of mouse embryonic fibroblast cells 
(MEFs) from PPM1A-knockout mice. While the impact of PPM1A on RanBP3 phosphorylation 
was reported, its role on SMAD2/3 phosphorylation was not (32). It will be extremely interesting 
to find out how TGFβ induced phosphorylation of SMAD2/3-tail is affected in these cells. 
Furthermore, PPM1A-/- MEFs would also be ideal negative controls for investigating the 
subcellular localisation of PPM1A. 
 
Upon identification of PP5 as an interactor of SMAD2/3 by mass spectrometry, we assessed its 
role in the TGFβ pathway as a potential SMAD2/3-tail phosphatase. Any SMAD2/3 phosphatase 
would be expected to physically associate with its substrate. We verified the interactions between 
SMAD2/3 and PP5 at the endogenous level in the extracts. Furthermore, we were able to 
demonstrate that PP5, under overexpression conditions, was capable of dephosphorylating 
Activin A-induced phospho-SMAD3. This observation alone, however, does not provide any 
evidence for a role of PP5 in the TGFβ pathway, as we would expect a similar observation with 
the overexpression of many phosphatases. In order to test whether PP5 had any effects on TGFβ 
pathway, we employed MEFs derived from PP5-null mice. Interestingly, TGFβ-induced 
transcriptional responses were enhanced in PP5-null MEFs compared to wild type. Consistent 
with this, the TGFβ-induced phosphorylation of SMAD3 was also enhanced in PP5-null MEFs 
compared to the wild type. However, the levels of SMAD3 were also higher in PP5-null MEFs 
compared to the wild type. This suggested that PP5 could regulate the expression of SMAD3 
protein in cells. Although the SMAD3 protein levels were affected in PP5-null cells compared to 
the wild type, the SMAD3 mRNA levels were unaltered suggesting PP5 might regulate SMAD3 
levels post-transcriptionally. The proteasomal inhibitors MG-132 and Bortezomib did not 
significantly enhance the levels of SMAD3 in wild type MEFs implying that PP5 is unlikely to 
be promoting proteasome-mediated degradation of SMAD3. We wanted to ensure the differences 
seen in the levels of SMAD3 in wild type and PP5-null MEFs was not due to differences in cell 
types. Therefore, we stably re-introduced wild type or a catalytically inactive mutant of PP5 in 
PP5-null MEFs. While re-introduction of wild type PP5 resulted in a decrease in levels of 
SMAD3, and consequently a decrease in levels of TGFβ-induced phospho-SMAD3, the 
catalytically inactive mutant of PP5 did not. This indicated that the catalytic activity of PP5 is 
essential for the regulation of SMAD3 levels in MEFs. Precisely how PP5 regulates SMAD3 
expression levels will be key to understanding its role in the TGFβ pathway. A phosphatase 
controlling the TGFβ pathway without directly dephosphorylating key TGFβ pathway mediators 
has been reported recently. PP4 was demonstrated to interact with SMAD1/5 in a transcriptional 
complex to promote BMP signalling (33). 
 
There are several issues to consider when contemplating the roles for PP5 in the TGFβ pathway. 
Firstly, this study has analysed the roles of PP5 on the TGFβ pathway primarily in MEFs. 
Experiments on other cells derived from PP5-null mice will help establish whether the roles of 
PP5 on TGFβ pathway are ubiquitous or restricted to MEFs. Secondly, that the PP5 activity 
regulates SMAD3 levels in MEFs is quite clear, but whether PP5 also dephosphorylates 
SMAD2/3-tail is not. The fact that PP5 interacts with SMAD2/3 and is capable of 
dephosphorylating SMAD2/3-tail under overexpression conditions implies that PP5 could 
potentially act as SMAD2/3 phosphatase. However, the association of PP5 with SMAD2/3 was 
not dependent on TGFβ-induction, suggesting that the interaction may have other cellular roles. 
It could be that other SMAD2/3 interacting partners could be dephosphorylated by PP5. Thirdly, 
PP5 has been implicated in the regulation of multiple pathways, including adipogenesis by 
controlling the GRα and PPARγ phosphorylation (34), DNA-damage repair by controlling the 
ATM/ATR/Chk1 and p53 pathway components (21,31,34-37), MAPK-mediated growth and 
differentiation (38-44), and cell cycle arrest (45). Interestingly, GRα has also been implicated in 
the repression of the TGFβ pathway by its association with SMAD3 (46). How these roles of 
PP5 relate to its potential impact on TGFβ pathway is still unknown. Furthermore, the lack of 
severe and apparent phenotypes in PP5-null mice generated by two laboratories independently 
implies that during development PP5 may not play a critical role in regulating the extent and 
duration of the TGFβ pathway (31,47). 
 
5. Conclusions 
 
- PPM1A/B are cytoplasmic phosphatases 
- PP5 interacts with SMADs2 and 3 
- TGFβ pathway signalling is enhanced in PP5-null MEFs 
- PP5 controls the levels of SMAD3 protein but not transcripts in MEFs 
- PP5 catalytic activity is essential for its control of SMAD3 levels in MEFs 
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FIGURE LEGENDS 
 
Fig. 1. PPM1A/B are cytoplasmic phosphatases. (A) HaCaT, mouse ES, MDA231, HUVEC 
and HEK293 cells were separated into cytosolic and nuclear fractions. Each fraction was 
immunoblotted with anti-PPM1A or PPM1B antibodies, as well as GAPDH (cytosol) and 
Histone H1B (nucleus) as markers of the fractionation. As a control, extracts from HaCaT cells 
transfected with siRNAs targeting PPM1A (iPPM1A) or FoxO4 (iFoxO4) were immunoblotted as 
indicated. (B) As in A except HeLa, MEFs, Swiss 3T3, HePG2, RAW, Neuro2A, G361 and U87 
cells were fractionated into nuclear and cytoplasmic fractions and immunoblotted with the 
indicated antibodies. The long exposures for PPM1A immunoblots are intentionally included to 
demonstrate very clear cytoplasmic localisation of PPM1A in all the cells. (C) HaCaT cells 
transfected with a construct encoding HA-tagged PPM1A were analysed by immunostaining 
with an antibody against the HA-tag (upper panel) or separated into nuclear and cytoplasmic 
fractions and immunoblotted with the indicated antibodies (lower panel). (D) HaCaT cells 
transfected with siRNAs targeting PPM1B (iPPM1B) or FoxO4 (iFoxO4) were analysed by 
immunostaining with a PPM1B antibody (upper panel) or separated into nuclear and cytoplasmic 
fractions and immunoblotted along with the cell extracts (lower panel). 
 
Fig. 2. The cytoplasmic localisation of PPM1A is unaffected by TGFβ/BMP treatment. (A) 
HaCaT cells were stimulated with a time course of TGFβ (50pM) and then fractionated into 
cytoplasmic and nuclear fractions. Expression of PPM1A was analysed by immunoblotting. 
Lamin A/C and GAPDH immunoblots were used as controls for efficient fractionation. The long 
exposures for PPM1A immunoblots are intentionally included to demonstrate very clear 
cytoplasmic localisation of PPM1A in all the cells. (B) As in A except that HaCaT cells were 
subjected to a time course of BMP (25ng/ml) treatment. 
 
Fig. 3. PP5 selectively interacts with SMAD2/3 but not SMAD1. (A) HaCaT cells were 
treated with or without TGFβ (50pM) for 1h prior to lysis in the presence of crosslinker DSP. 
500µg protein lysates were subjected to immunoprecipitation with pre-immune IgG or antibodies 
against SMAD2 and SMAD3. Extracts (20µg) and IPs were subjected to SDS-PAGE and 
immunoblotted with the indicated antibodies. (B) As in A except that A549 cells were used and 
treated with or without Activin A (20ng/ml) and BMP (25ng/ml) as indicated for 1h before lysis. 
Extracts or the indicated IPs were subjected to SDS-PAGE and immunoblotted with the 
indicated antibodies. 
 
Fig. 4. Role for okadaic acid (OA)-sensitive phosphatases in the TGFβ pathway (A) 
Schematic diagram depicting the time points that cells were treated with ligands or inhibitors, 
washed and lysed. HaCaT cells were stimulated with TGFβ (25pM) for 45min, in the presence or 
absence of OA (20nM), and then washed and incubated at 37°C for a further 120min. Cells were 
lysed at each time point and extracts were subjected to immunoblotting with the indicated 
antibodies. (B) HEK293 cells were transfected with HA-tagged PP5, alone or with FLAG-
SMADs, for 48h. Cells were stimulated 1h before lysis with Activin A (20ng/ml). Extracts were 
immunoblotted with the indicated antibodies. (C) Same as C except cells were stimulated with 
BMP-2 (25ng/ml). 
 
Fig. 5. TGFβ-induced transcription is enhanced in PP5-null MEFs (A) PP5 wild type (+/+) 
and PP5-null (-/-) MEFs were transfected, in triplicate, with either 400ng/well of SRE-Lux or 
3TP-Lux – both TGFβ-responsive transcription reporter constructs. The transfections were 
controlled with 40ng/well Renilla. After 16h, cells were stimulated with or without TGFβ 
(25pM) in the presence or absence of 10µM SB-431542 for 6h prior to lysis in passive 
conditions. Error bars represent the standard deviation of 3 independent experiments. (B) As in A 
except that BMP-responsive luciferase construct BRE-Lux was used in conjunction with BMP 
(25ng/ml) stimulation and the use of the BMP-type I receptor inhibitor (LDN-193189 at 100nM). 
(C) RNA was isolated from PP5+/+ or PP5-/- MEFs following a TGFβ (25pM) time course. 
cDNA was synthesised and the expression of indicated TGFβ target genes was assessed by qRT-
PCR. The fold change in gene expression was measured relative to the untreated PP5+/+ MEFs. 
The experiment was repeated 3 times. (D) RNA was isolated from PP5+/+ or PP5-/- MEFs in the 
absence of TGFβ stimulation and qRT-PCR was performed using SMAD3 specific primers 
(n=6). 
 
Fig. 6. PP5 alters the levels of SMAD3 protein in MEFs. (A) Wild type (+/+) and PP5-null (-/-
) MEFs were stimulated with TGFβ (5pM or 25pM) for indicated times prior to lysis. Cell 
extracts were subjected to SDS-PAGE and immunoblotting with the indicated antibodies. (B) As 
in A except cells were stimulated with 25pM TGFβ for 45min, washed and either lysed or 
incubated in DMEM at 37°C for indicated times before lysis. (C) As in A except cells were pre-
treated with the proteasome inhibitors Bortezomib (10µM) or MG-132 (10µg/ml) for 2h before 
stimulation with TGFβ (25pM) for 1h.  
 
Fig. 7. PP5 catalytic activity controls the expression of SMAD3 protein in MEFs. (A) PP5 (-
/-) MEF cells were infected with retroviruses encoding wild type (WT) PP5, catalytically 
inactive (PD) mutant of PP5 or empty vector controls. Cell extracts were subjected to SDS-
PAGE and blotted with the PP5 antibody. (B) As in A except cells were stimulated with TGFβ 
(5pM or 25pM) for 45min prior to lysis. The extracts were separated by SDS-PAGE and 
immunoblotted with the indicated antibodies. 
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